Vascular Biology in Clinical Practice
• The vascular endothelium and CAD: New target considerations in treating the cardiovascular dysmetabolic syndrome
This discourse is based on the proceedings of a national faculty meeting of the Vascular Biology Working Group held in Orlando earlier this year that explored the clustering of metabolic abnormalities associated with what previously has been recognized by many as "syndrome X."
A more descriptive term has been suggested that encompasses the total set of cardiovascular risk factors which frequently coexist in many patients: the Cardiovascular Dysmetabolic Syndrome (CDS).
The view by the faculty in this program is that treating each patient's total cardiovascular risk and recognizing therapeutic opportunities to improve underlying disease pathology is an important part of addressing CDS. The overall subtext is to realize the important role of the endothelium in maintenance of vascular tone and structure.
Donald Hunninghake, MD
C. Noel Bairey Merz, MD
Steven E. Nissen, MD
Carl J. Pepine, MD
Jorge Plutzky, MD
Burton Sobel, MD
Howard S. Weintraub, MD
Peter N. Weissman, MD